
SK biopharmaceuticals
Developing innovative and next-generation drugs for central nervous system.
Market cap
$6.0b
Enterprise value
$5.9b
Share price
KRW92500.00 326030.KS
Recent deals
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
* | $180m | Series A | |
* | N/A | Grant | |
Total Funding | $180m |

Korea Drug Development Fund(exited)

KB Investment(exited)

HBM Healthcare Investments(exited)

Goldman Sachs(exited)

Mubadala Capital(exited)

WTT Investment(exited)
KRW | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | (41 %) | 44 % | 54 % | 28 % | 29 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 21 % | (46 %) | (3 %) | 20 % | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 15 % | (57 %) | (9 %) | 44 % | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 27 % | 50 % | 39 % | 29 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by SK biopharmaceuticals
Edit
ACQUISITION by SK biopharmaceuticals Jun 2023